The authors discuss the current treatment landscape and detail their approach to first-line immunotherapy regimen selection for patients with advanced-stage, driver-negative NSCLC.
[Nature Reviews Clinical Oncology]
7753456
{7753456:IM7KGJ45}
apa
50
1
163838
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-6a647b488ce1002389a7fef1701ffcc3%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22IM7KGJ45%22%2C%22library%22%3A%7B%22id%22%3A7753456%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Grant%20et%20al.%22%2C%22parsedDate%22%3A%222021-06-24%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGrant%2C%20M.%20J.%2C%20Herbst%2C%20R.%20S.%2C%20%26amp%3B%20Goldberg%2C%20S.%20B.%20%282021%29.%20Selecting%20the%20optimal%20immunotherapy%20regimen%20in%20driver-negative%20metastatic%20NSCLC.%20%3Ci%3ENature%20Reviews%20Clinical%20Oncology%3C%5C%2Fi%3E%2C%201%26%23x2013%3B20.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41571-021-00520-1%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41571-021-00520-1%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D7753456%26amp%3Bitem_key%3DIM7KGJ45%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Selecting%20the%20optimal%20immunotherapy%20regimen%20in%20driver-negative%20metastatic%20NSCLC%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20J.%22%2C%22lastName%22%3A%22Grant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roy%20S.%22%2C%22lastName%22%3A%22Herbst%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%20B.%22%2C%22lastName%22%3A%22Goldberg%22%7D%5D%2C%22abstractNote%22%3A%22The%20treatment%20landscape%20of%20driver-negative%20non-small-cell%20lung%20cancer%20%28NSCLC%29%20is%20rapidly%20evolving.%20Immune-checkpoint%20inhibitors%2C%20specifically%20those%20targeting%20PD-1%20or%20PD-L1%2C%20have%20demonstrated%20durable%20efficacy%20in%20a%20subset%20of%20patients%20with%20NSCLC%2C%20and%20these%20agents%20have%20become%20the%20cornerstone%20of%20first-line%20therapy.%20Approved%20immunotherapeutic%20strategies%20for%20treatment-naive%20patients%20now%20include%20monotherapy%2C%20immunotherapy-exclusive%20regimens%20or%20chemotherapy%5Cu2013immunotherapy%20combinations.%20Decision%20making%20in%20this%20space%20is%20complex%20given%20the%20absence%20of%20head-to-head%20prospective%20comparisons%2C%20although%20a%20thorough%20analysis%20of%20long-term%20efficacy%20and%20safety%20data%20from%20pivotal%20clinical%20trials%20can%20provide%20insight%20into%20the%20optimal%20management%20of%20each%20subset%20of%20patients.%20Indeed%2C%20histological%20subtype%20and%20the%20extent%20of%20tumour%20cell%20PD-L1%20expression%20are%20paramount%20to%20regimen%20selection%2C%20although%20other%20clinicopathological%20factors%20and%20patient%20preferences%20might%20also%20be%20relevant%20in%20certain%20scenarios.%20Finally%2C%20several%20emerging%20biomarkers%20and%20novel%20therapeutic%20strategies%20are%20currently%20under%20investigation%2C%20and%20these%20might%20further%20refine%20the%20current%20treatment%20paradigm.%20In%20this%20Review%2C%20we%20discuss%20the%20current%20treatment%20landscape%20and%20detail%20our%20approach%20to%20first-line%20immunotherapy%20regimen%20selection%20for%20patients%20with%20advanced-stage%2C%20driver-negative%20NSCLC.%22%2C%22date%22%3A%222021-06-24%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41571-021-00520-1%22%2C%22ISSN%22%3A%221759-4782%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41571-021-00520-1%22%2C%22deleted%22%3A1%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-06-24T17%3A30%3A09Z%22%7D%7D%5D%7D
Grant, M. J., Herbst, R. S., & Goldberg, S. B. (2021). Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nature Reviews Clinical Oncology, 1–20. https://doi.org/10.1038/s41571-021-00520-1 Cite
